NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Price Target & More

$66.68 -1.02 (-1.51 %)

(As of 04/24/2018 12:42 PM ET)

Previous Close$67.70

Today's Range$66.31 - $68.44

52-Week Range$51.05 - $135.59

Volume224,481 shs

Average Volume910,681 shs

Market Capitalization$2.02 billion

P/E Ratio-4.65

Dividend YieldN/A

Beta-1.81

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:ICPT

CUSIP45845P10

Webwww.interceptpharma.com

Phone646-747-1000

Debt

Debt-to-Equity Ratio21.71%

Current Ratio4.31%

Quick Ratio4.31%

Price-To-Earnings

Trailing P/E Ratio-4.65

Forward P/E Ratio-5.39

P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million

Price / Sales14.98

Cash FlowN/A

Price / CashN/A

Book Value$0.65 per share

Price / Book102.58

Profitability

EPS (Most Recent Fiscal Year)($14.38)

Net Income$-360,360,000.00

Net Margins-275.18%

Return on Equity-267.95%

Return on Assets-61.90%

Miscellaneous

Employees507

Outstanding Shares29,430,000

How to Become a New Pot Stock Millionaire

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals (NASDAQ:ICPT) released its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing analysts' consensus estimates of ($3.39) by $1.04. The biopharmaceutical company earned $37.69 million during the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. The company's quarterly revenue was up 173.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($4.84) EPS. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

21 brokerages have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $50.00 to $256.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $128.5263 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

1. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
2. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
3. Cantor Fitzgerald analysts commented, "Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher)." (11/1/2017)
4. Wells Fargo analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
5. Cowen Inc analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Some companies that are related to Intercept Pharmaceuticals include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
Dr. David Shapiro M.D., Ph.D., Chief Medical Officer (Age 64)
Ms. Lisa Bright B.Sc., Pres of International (Age 50)
Mr. Jerome B. Durso, Chief Operating Officer (Age 50)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News stories about ICPT stock have trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of 0.19 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.28 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include GENEXTRA S.P.A. (23.30%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $66.68.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.02 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		775 (Vote Outperform)
Underperform Votes:		398 (Vote Underperform)
Total Votes:		1,173

MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $128.5263, suggesting that the stock has a possible upside of 92.75%. The high price target for ICPT is $256.00 and the low price target for ICPT is $50.00. There are currently 3 sell ratings, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.33	2.33	2.36	2.24
Ratings Breakdown:	3 Sell Rating(s) 8 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 8 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 10 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 10 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$128.5263	$128.3684	$138.75	$153.85
Price Target Upside:	92.75% upside	106.11% upside	140.38% upside	148.47% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Wedbush	Lower Price Target	Outperform -> Outperform	$203.00 -> $256.00	Low
3/28/2018	Needham & Company LLC	Reiterated Rating	Hold		Medium
3/20/2018	Oppenheimer	Reiterated Rating	Hold		Low
2/15/2018	BMO Capital Markets	Boost Price Target	Outperform -> Outperform	$152.00 -> $155.00	High
2/14/2018	Cantor Fitzgerald	Set Price Target	Hold	$58.00	High
2/13/2018	Wells Fargo	Reiterated Rating	Market Perform	$62.00 -> $57.00	Medium
2/12/2018	Deutsche Bank	Initiated Coverage	Buy	$103.00	Medium
2/7/2018	Goldman Sachs	Downgrade	Neutral -> Sell		Low
1/25/2018	Robert W. Baird	Reiterated Rating	Outperform	$332.00 -> $253.00	Low
1/22/2018	Credit Suisse Group	Set Price Target	Buy	$201.00 -> $167.00	High
12/29/2017	Citigroup	Set Price Target	Hold	$74.00	High
11/28/2017	Leerink Swann	Reiterated Rating	Hold	$60.00	Low
11/1/2017	Cowen	Reiterated Rating	Buy	$112.00	N/A
11/1/2017	Laidlaw	Upgrade	Hold -> Buy	$90.00	N/A
10/13/2017	Bank of America	Lower Price Target	Underperform	$102.00 -> $73.00	N/A
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy	$136.00	N/A
10/4/2017	Royal Bank of Canada	Reiterated Rating	Outperform -> Outperform		High
10/4/2017	JMP Securities	Downgrade	Outperform -> Market Perform		High
9/26/2017	Jefferies Group	Reiterated Rating	Buy	$275.00 -> $135.00	Low
9/22/2017	UBS	Downgrade	Outperform -> Market Perform		Low
9/22/2017	Morgan Stanley	Reiterated Rating	Underweight	$75.00 -> $50.00	High
2/16/2017	FBR & Co	Reiterated Rating	Market Perform	$200.00	N/A
6/1/2016	Barclays	Reiterated Rating	Buy	$200.00 -> $205.00	N/A

(Data available from 4/24/2016 forward)

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings History and Estimates Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates

2018 EPS Consensus Estimate: ($13.73)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	($3.71)	($3.32)	($3.44)
Q2 2018	4	($4.12)	($2.89)	($3.36)
Q3 2018	4	($4.63)	($2.81)	($3.36)
Q4 2018	4	($5.23)	($2.74)	($3.57)

Intercept Pharmaceuticals (NASDAQ ICPT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		($3.38)					N/A
2/14/2018	Q4 2017	($3.39)	($4.43)	$39.01 million	$37.69 million	View	N/A
11/1/2017	Q3 2017	($3.48)	($2.89)	$36.95 million	$41.33 million	View	N/A
7/31/2017	Q2 2017	($3.62)	($3.46)	$27.50 million	$30.89 million	View	N/A
5/4/2017	Q1 2017	($4.27)	($3.61)	$15.88 million	$21.00 million	View	Listen
2/23/2017	Q416	($3.74)	($4.84)	$8.96 million	$13.00 million	View	N/A
11/3/2016	Q316	($3.82)	($3.59)	$4.77 million	$4.70 million	View	N/A
8/4/2016	Q216	($3.69)	($3.14)	$1.72 million	$5.52 million	View	N/A
5/5/2016	Q1	($3.60)	($3.33)	$0.49 million	$0.45 million	View	N/A
2/23/2016	Q415	($3.15)	($3.62)	$0.43 million	$0.45 million	View	Listen
11/9/2015	Q315	($2.74)	($2.10)	$0.42 million	$0.45 million	View	N/A
8/5/2015	Q215	($1.95)	($1.99)	$2.17 million	$0.45 million	View	N/A
5/11/2015	Q115	($1.75)	($1.78)	$1.70 million	$1.70 million	View	Listen
3/2/2015	Q414	($1.53)	($1.63)	$0.42 million	$0.04 million	View	N/A
11/6/2014	Q3	($1.10)	($1.69)	$0.46 million	$0.45 million	View	N/A
8/11/2014	Q214	($1.10)	$1.51	$400.00 million	$405.40 million	View	N/A
5/7/2014	Q1 2014	($0.72)	($1.59)	$0.41 million	$0.41 million	View	N/A
3/14/2014	Q4 13	($0.70)	($0.64)	$0.41 million	$0.41 million	View	N/A
11/14/2013	Q313	($0.51)	($1.65)	$0.89 million	$0.41 million	View	N/A
8/13/2013	Q2 2013	($0.51)	($0.79)	$0.40 million	$0.4050 million	View	N/A
5/14/2013	Q1 2013	($0.44)	($0.62)	$1.23 million	$0.41 million	View	N/A
3/18/2013	Q4 2012	($0.37)	($0.43)			View	N/A
11/26/2012	Q3 2012	($0.57)	($1.86)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Intercept Pharmaceuticals (NASDAQ:ICPT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 63.29%

Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/9/2018	Francesco Micheli	Major Shareholder	Buy	390,625	$64.00	$25,000,000.00
4/9/2018	Keith Michael Gottesdiener	Director	Buy	1,171	$64.00	$74,944.00	5,001
4/9/2018	Mark Pruzanski	CEO	Buy	7,812	$64.00	$499,968.00	11,642
10/2/2017	David Shapiro	CMO	Sell	349	$58.90	$20,556.10
10/2/2017	Mark Pruzanski	CEO	Sell	1,532	$58.87	$90,188.84
10/2/2017	Rachel Mcminn	Insider	Sell	283	$58.89	$16,665.87
10/2/2017	Richard J Kim	SVP	Sell	48	$58.10	$2,788.80
10/2/2017	Sandip Kapadia	CFO	Sell	354	$58.83	$20,825.82
9/1/2017	David Shapiro	CMO	Sell	1,250	$117.43	$146,787.50	45,812
8/25/2017	Lisa Bright	Insider	Sell	253	$111.31	$28,161.43	23,324
8/2/2017	Lisa Bright	Insider	Sell	142	$110.29	$15,661.18	23,477
8/1/2017	David Shapiro	CMO	Sell	1,118	$119.00	$133,042.00	45,680
7/31/2017	Daniel G Welch	Director	Sell	602	$123.93	$74,605.86	3,108
7/31/2017	Rachel Mcminn	Insider	Sell	130	$123.12	$16,005.60	17,158
7/20/2017	Daniel G Welch	Director	Sell	217	$126.76	$27,506.92	3,710
7/14/2017	Richard J Kim	SVP	Sell	89	$128.64	$11,448.96	11,253
7/11/2017	David Shapiro	CMO	Sell	553	$124.01	$68,577.53	44,562
7/3/2017	David Shapiro	CMO	Sell	350	$121.24	$42,434.00	45,215
7/3/2017	Lisa Bright	Insider	Sell	394	$121.33	$47,804.02	23,619
7/3/2017	Mark Pruzanski	CEO	Sell	1,434	$121.78	$174,632.52	570,284
7/3/2017	Richard J Kim	SVP	Sell	50	$121.69	$6,084.50	11,342
7/3/2017	Sandip Kapadia	CFO	Sell	1,431	$121.59	$173,995.29	20,569
6/26/2017	Mark Pruzanski	CEO	Sell	40,000	$130.80	$5,232,000.00	611,718
6/1/2017	Lisa Bright	Insider	Sell	698	$110.73	$77,289.54	24,711
5/25/2017	Lisa Bright	Insider	Sell	254	$117.52	$29,850.08	23,246
5/16/2017	Lisa Bright	Insider	Sell	113	$119.74	$13,530.62	23,613
5/2/2017	Lisa Bright	Insider	Sell	426	$114.00	$48,564.00	23,804
5/1/2017	David Shapiro	CMO	Sell	1,117	$112.18	$125,305.06	46,582
5/1/2017	Rachel Mcminn	Insider	Sell	114	$113.12	$12,895.68	17,545
4/10/2017	David Shapiro	CMO	Sell	558	$108.51	$60,548.58	45,465
4/3/2017	David Shapiro	CMO	Sell	346	$115.00	$39,790.00	46,023
4/3/2017	Lisa Bright	Insider	Sell	389	$115.00	$44,735.00	22,925
4/3/2017	Mark Pruzanski	CEO	Sell	1	$115.00	$115.00	571,718
2/27/2017	Lisa Bright	Insider	Sell	254	$119.48	$30,347.92	21,695
1/31/2017	Lisa Bright	Insider	Sell	134	$108.96	$14,600.64	17,383
1/9/2017	David Shapiro	CMO	Sell	1,565	$106.01	$165,905.65	40,369
1/3/2017	David Shapiro	CMO	Sell	988	$103.92	$102,672.96	41,934
1/3/2017	Mark Pruzanski	CEO	Sell	2,802	$103.92	$291,183.84	552,705
1/3/2017	Rachel Mcminn	Insider	Sell	816	$103.92	$84,798.72	12,916
12/2/2016	David Shapiro	CMO	Sell	1,350	$99.75	$134,662.50	42,922
11/25/2016	Lisa Bright	Insider	Sell	249	$113.60	$28,286.40	18,209
10/31/2016	Rachel Mcminn	Insider	Sell	129	$123.82	$15,972.78	13,732
10/10/2016	David Shapiro	CMO	Sell	411	$153.34	$63,022.74	44,272
10/3/2016	Barbara Gayle Duncan	CAO	Sell	147	$163.20	$23,990.40	30,661
10/3/2016	David Shapiro	CMO	Sell	1,513	$163.08	$246,740.04	46,196
10/3/2016	Lisa Bright	Insider	Sell	155	$163.20	$25,296.00	18,305
10/3/2016	Mark Pruzanski	CEO	Sell	705	$163.20	$115,056.00	552,020
9/26/2016	David Shapiro	CMO	Sell	3,545	$165.08	$585,208.60	45,732
9/20/2016	Mark Pruzanski	CEO	Sell	35,000	$165.00	$5,775,000.00	579,314
8/25/2016	Lisa Bright	Insider	Sell	246	$159.00	$39,114.00	18,460
8/1/2016	Rachel Mcminn	Insider	Sell	125	$176.57	$22,071.25	13,861
7/5/2016	Barbara Gayle Duncan	CAO	Sell	146	$145.11	$21,186.06
7/5/2016	David Shapiro	CMO	Sell	163	$145.11	$23,652.93
7/5/2016	Lisa Bright	Insider	Sell	155	$145.11	$22,492.05
7/5/2016	Mark Pruzanski	CEO	Sell	714	$145.11	$103,608.54
5/25/2016	Lisa Bright	Insider	Sell	251	$137.50	$34,512.50	18,855
5/2/2016	Rachel Mcminn	Insider	Sell	130	$147.49	$19,173.70	14,087
4/4/2016	Barbara Gayle Duncan	CFO	Sell	144	$130.76	$18,829.44	30,948
4/4/2016	David Shapiro	CMO	Sell	165	$130.76	$21,575.40	48,546
4/4/2016	Lisa Bright	Insider	Sell	153	$130.76	$20,006.28	19,106
4/4/2016	Mark Pruzanski	CEO	Sell	708	$130.76	$92,578.08	548,248
2/25/2016	Lisa Bright	Insider	Sell	241	$115.22	$27,768.02	19,259
2/1/2016	Rachel Mcminn	Insider	Sell	128	$103.56	$13,255.68	7,621
1/13/2016	Lisa Bright	insider	Sell	728	$125.52	$91,378.56	11,700
1/4/2016	Barbara Gayle Duncan	CFO	Sell	468	$145.90	$68,281.20	24,892
1/4/2016	David Shapiro	CMO	Sell	533	$145.90	$77,764.70	40,911
1/4/2016	Mark Pruzanski	CEO	Sell	2,126	$145.90	$310,183.40	529,556
1/4/2016	Rachel Mcminn	Insider	Sell	469	$145.90	$68,427.10	7,749
11/25/2015	Lisa Bright	Insider	Sell	1,150	$182.96	$210,404.00	12,428
11/16/2015	David Shapiro	CMO	Sell	4,264	$178.53	$761,251.92	28,395
11/10/2015	David Shapiro	CMO	Sell	3,500	$204.15	$714,525.00	29,159
11/10/2015	Klaus R. Dr Veitinger	Director	Sell	1,000	$198.25	$198,250.00	2,166
11/2/2015	Rachel Mcminn	Insider	Sell	125	$160.24	$20,030.00	8,218
10/2/2015	Barbara Gayle Duncan	CFO	Sell	1,054	$163.17	$171,981.18	24,062
10/2/2015	David Shapiro	CMO	Sell	1,140	$160.12	$182,536.80	29,159
9/21/2015	Nicole Williams	Director	Sell	973	$194.82	$189,559.86	962
9/15/2015	David Shapiro	CMO	Sell	3,500	$191.28	$669,480.00	23,527
8/17/2015	David Shapiro	CMO	Sell	4,272	$209.37	$894,428.64
7/20/2015	Nicole Williams	Director	Sell	973	$279.01	$271,476.73
7/10/2015	Mark Pruzanski	CEO	Sell	12,500	$250.00	$3,125,000.00
7/6/2015	Luciano Adorini	Insider	Sell	4,067	$579.93	$2,358,575.31
7/1/2015	Barbara Gayle Duncan	CFO	Sell	1,000	$242.10	$242,100.00
7/1/2015	David Shapiro	CMO	Sell	3,781	$238.66	$902,373.46
6/22/2015	Nicole Williams	Director	Sell	974	$265.14	$258,246.36
6/15/2015	David Shapiro	CMO	Sell	3,500	$241.58	$845,530.00
6/8/2015	Luciano Adorini	Insider	Sell	4,000	$248.40	$993,600.00
5/11/2015	Klaus R Dr Veitinger	Director	Sell	391	$279.07	$109,116.37
5/6/2015	Luciano Adorini	Insider	Sell	4,000	$259.97	$1,039,880.00
4/20/2015	Nicole Williams	Director	Sell	974	$278.50	$271,259.00
4/6/2015	Luciano Adorini	Insider	Sell	4,000	$269.64	$1,078,560.00
4/2/2015	David Shapiro	CMO	Sell	3,459	$275.25	$952,089.75
3/26/2015	Orbimed Advisors Llc	Director	Sell	157,200	$286.75	$45,077,100.00
3/25/2015	Orbimed Advisors Llc	Director	Sell	207,800	$274.41	$57,022,398.00
3/24/2015	Jonathan Silverstein	Director	Sell	45,600	$272.00	$12,403,200.00
3/23/2015	Jonathan Silverstein	Director	Sell	159,400	$275.18	$43,863,692.00
3/16/2015	David Shapiro	CMO	Sell	3,500	$286.90	$1,004,150.00
1/12/2015	Klaus R Dr Veitinger	Director	Sell	233	$150.01	$34,952.33
1/5/2015	Barbara Gayle Duncan	CFO	Sell	141	$176.49	$24,885.09
1/5/2015	Daniel Paul Regan	Insider	Sell	146	$176.49	$25,767.54
1/5/2015	David Shapiro	CMO	Sell	664	$172.63	$114,626.32
1/5/2015	Mark Pruzanski	CEO	Sell	461	$176.49	$81,361.89
1/2/2015	Barbara Gayle Duncan	CFO	Sell	1,000	$156.40	$156,400.00
11/17/2014	David Shapiro	CMO	Sell	4,790	$158.82	$760,747.80
11/12/2014	Srinivas Akkaraju	Director	Buy	2,000	$167.19	$334,380.00
11/10/2014	Klaus R Dr Veitinger	Director	Sell	233	$175.95	$40,996.35
11/3/2014	Mark Pruzanski	CEO	Sell	10,000	$259.41	$2,594,100.00
10/10/2014	Klaus R Dr Veitinger	Director	Sell	391	$223.65	$87,447.15
10/2/2014	David Shapiro	CMO	Sell	5,020	$231.63	$1,162,782.60
10/1/2014	Barbara Gayle Duncan	CFO	Sell	1,000	$233.12	$233,120.00
10/1/2014	David Shapiro	CMO	Sell	4,188	$231.17	$968,139.96
10/1/2014	Mark Pruzanski	CEO	Sell	10,000	$228.82	$2,288,200.00
9/15/2014	David Shapiro	CMO	Sell	4,000	$281.19	$1,124,760.00
9/10/2014	Klaus R Dr Veitinger	Director	Sell	391	$280.50	$109,675.50
9/2/2014	Mark Pruzanski	CEO	Sell	10,000	$286.49	$2,864,900.00
8/27/2014	David Shapiro	CMO	Sell	10,000	$293.93	$2,939,300.00
8/26/2014	Orbimed Advisors Llc	Director	Sell	111,258	$298.06	$33,161,559.48
8/25/2014	Jonathan Silverstein	Director	Sell	50,000	$295.59	$14,779,500.00
8/15/2014	David Shapiro	CMO	Sell	4,774	$291.49	$1,391,573.26
8/12/2014	Daniel Paul Regan	Insider	Sell	8,124	$325.70	$2,645,986.80
8/12/2014	Klaus R Dr Veitinger	Director	Sell	316	$345.62	$109,215.92
8/1/2014	Mark Pruzanski	CEO	Sell	10,000	$226.72	$2,267,200.00
7/10/2014	Klaus R Dr Veitinger	Director	Sell	391	$219.15	$85,687.65
7/7/2014	Lorenzo Tallarigo	Director	Sell	2,000	$243.06	$486,120.00
7/2/2014	David Shapiro	CMO	Sell	5,036	$244.73	$1,232,460.28
7/1/2014	Mark Pruzanski	CEO	Sell	10,000	$250.61	$2,506,100.00
6/16/2014	David Shapiro	CMO	Sell	4,000	$278.15	$1,112,600.00
6/2/2014	Mark Pruzanski	CEO	Sell	10,000	$230.60	$2,306,000.00
5/9/2014	Lorenzo Tallarigo	Director	Sell	2,007	$254.68	$511,142.76
5/1/2014	Mark Pruzanski	CEO	Sell	10,000	$263.17	$2,631,700.00	470,174
4/16/2014	Mark Pruzanski	CEO	Sell	10,000	$242.22	$2,422,200.00	470,174
4/14/2014	Barbara Gayle Duncan	CFO	Sell	1,154	$279.00	$321,966.00	13,510
4/10/2014	Lorenzo Tallarigo	Director	Sell	349,318	$317.71	$110,981,821.78	1,640
4/9/2014	Orbimed Advisors Llc	Director	Sell	81,305	$320.00	$26,017,600.00
4/7/2014	Luciano Adorini	Insider	Sell	2,000	$283.90	$567,800.00	7,041
4/2/2014	David Shapiro	CMO	Sell	5,393	$331.83	$1,789,559.19	13,679
3/17/2014	David Shapiro	CMO	Sell	4,456	$437.49	$1,949,455.44	13,124
2/14/2014	Paolo Fundaro	Director	Sell	7,246	$375.26	$2,719,133.96	1,655
1/16/2014	Mark Pruzanski	CEO	Sell	10,000	$273.68	$2,736,800.00	430,298
1/16/2014	Srinivas Akkaraju	Director	Sell	3,250	$267.94	$870,805.00	1,943
1/8/2014	David Shapiro	CMO	Sell	4,928	$71.85	$354,076.80	8,663
1/7/2014	Lorenzo Tallarigo	Director	Sell	1,839	$67.41	$123,966.99	1,640
1/7/2014	Luciano Adorini	Insider	Sell	1,634	$67.41	$110,147.94	6,392
12/16/2013	David Shapiro	CMO	Sell	5,016	$62.11	$311,543.76	3,000
10/21/2013	Francesco Micheli	Major Shareholder	Sell	124,912	$62.50	$7,807,000.00
10/21/2013	Jonathan Silverstein	Director	Sell	40,088	$62.50	$2,505,500.00
10/21/2013	Luciano Adorini	Insider	Sell	2,000	$55.51	$111,020.00
10/15/2013	Francesco Micheli	Major Shareholder	Sell	1,123,415	$62.50	$70,213,437.50
10/15/2013	Orbimed Advisors Llc	Director	Sell	376,585	$62.50	$23,536,562.50
10/2/2013	David Shapiro	CMO	Sell	4,392	$72.80	$319,737.60
9/20/2013	Luciano Adorini	Insider	Sell	2,000	$61.07	$122,140.00	5,094
9/17/2013	Mark Pruzanski	CEO	Sell	25,000	$52.00	$1,300,000.00	402,032
9/13/2013	Mark Pruzanski	CEO	Sell	12,500	$49.02	$612,750.00	402,032
8/20/2013	Luciano Adorini	Insider	Sell	2,000	$44.18	$88,360.00	5,094
8/16/2013	David Shapiro	CMO	Sell	5,016	$49.20	$246,787.20	4,266
8/15/2013	David Shapiro	CMO	Sell	4,754	$45.04	$214,120.16	2,532
8/12/2013	Mark Pruzanski	CEO	Sell	12,500	$45.98	$574,750.00	402,032
8/12/2013	Paolo Fundaro	Director	Sell	4,759	$46.13	$219,532.67	1,330
7/22/2013	Luciano Adorini	Insider	Sell	2,000	$49.44	$98,880.00
7/15/2013	Mark Pruzanski	CEO	Sell	25,000	$50.05	$1,251,250.00
7/9/2013	Mark Pruzanski	CEO	Sell	37,500	$46.36	$1,738,500.00
7/8/2013	Barbara Gayle Duncan	CFO	Sell	25,000	$45.39	$1,134,750.00
7/2/2013	David Shapiro	CMO	Sell	4,369	$43.63	$190,619.47
6/26/2013	Mark Pruzanski	CEO	Sell	12,500	$40.06	$500,750.00
6/20/2013	Luciano Adorini	Insider	Sell	2,000	$37.07	$74,140.00
6/20/2013	Mark Pruzanski	CEO	Sell	25,000	$38.25	$956,250.00
6/19/2013	Barbara Gayle Duncan	CFO	Sell	50,575	$34.50	$1,744,837.50
6/17/2013	David Shapiro	CMO	Sell	5,016	$32.72	$164,123.52
5/28/2013	Barbara Gayle Duncan	CFO	Sell	6,225	$34.50	$214,762.50
5/20/2013	Barbara Gayle Duncan	CFO	Sell	28,200	$34.50	$972,900.00
5/16/2013	David Shapiro	CMO	Sell	5,016	$31.31	$157,050.96
4/9/2013	David Shapiro	CMO	Sell	3,750	$34.41	$129,037.50
10/16/2012	Jonathan Silverstein	Director	Buy	333,334	$15.00	$5,000,010.00

(Data available from 1/1/2013 forward)

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:

Date	Headline
	Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors finance.yahoo.com - April 24 at 8:42 AM
	Research Analysts Set Expectations for Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT) www.americanbankingnews.com - April 19 at 7:08 AM
	BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Buy" www.americanbankingnews.com - April 18 at 10:06 AM
	Jefferies Group Weighs in on Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT) www.americanbankingnews.com - April 18 at 7:54 AM
	Intercept Pharmaceuticals (ICPT) Given New $256.00 Price Target at Wedbush www.americanbankingnews.com - April 17 at 8:49 AM
	Intercept Reports Phase III Sub-Study Liver Biopsy Data www.zacks.com - April 16 at 5:01 PM
	Intercept Pharmaceuticals (ICPT) Receives Hold Rating from Laidlaw www.americanbankingnews.com - April 14 at 2:30 PM
	11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA) globenewswire.com - April 13 at 8:55 AM
	Intercept Pharma's obeticholic acid shows positive effect on fibrosis and cirrhosis in late-stage study; shares up 3% premarket seekingalpha.com - April 13 at 8:55 AM
	CymaBay Therapeutics Pushes Itself To The Next Stage Against Rare Liver Disease seekingalpha.com - April 12 at 9:21 AM
	Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Quarterly Sales of $38.55 Million www.americanbankingnews.com - April 10 at 2:56 AM
	Intercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in Stock www.americanbankingnews.com - April 9 at 10:26 PM
	Intercept Pharmaceuticals Inc (ICPT) Director Keith Michael Gottesdiener Acquires 1,171 Shares www.americanbankingnews.com - April 9 at 10:26 PM
	Intercept Pharmaceuticals Inc (ICPT) Major Shareholder Francesco Micheli Purchases 390,625 Shares www.americanbankingnews.com - April 9 at 7:16 PM
	A Look at Intercept Pharmaceuticals’ Cash Flows finance.yahoo.com - April 9 at 8:54 AM
	Royal Bank of Canada Raises Intercept Pharmaceuticals (ICPT) Price Target to $244.00 www.americanbankingnews.com - April 8 at 5:25 PM
	Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Earnings of -$3.42 Per Share www.americanbankingnews.com - April 8 at 3:10 PM
	Intercept Pharmaceuticals (ICPT) Cut to "Market Perform" at JMP Securities www.americanbankingnews.com - April 7 at 10:28 PM
	Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April finance.yahoo.com - April 7 at 9:04 AM
	Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher www.zacks.com - April 6 at 8:56 AM
	Today’s Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals finance.yahoo.com - April 6 at 8:56 AM
	Analysts’ Ratings for Intercept Pharmaceuticals in April finance.yahoo.com - April 6 at 8:56 AM
	Intercept Pharma (ICPT) Plans $120 Million Public Offering of Common Stock, Concurrent $92 Million Private Placement www.streetinsider.com - April 5 at 4:59 PM
	Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today finance.yahoo.com - April 5 at 4:59 PM
	Intercept Pharmaceuticals (ICPT) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 5 at 1:11 PM
	Intercept Pharma prices upsized stock offering at $64; shares up 1% premarket seekingalpha.com - April 5 at 10:47 AM
	Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock finance.yahoo.com - April 5 at 10:47 AM
	Intercept Pharmaceuticals (ICPT) Upgraded at Laidlaw www.americanbankingnews.com - April 2 at 11:16 AM
	Intercept Pharmaceuticals Inc (ICPT) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - March 31 at 8:11 AM
	Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 29 at 10:49 PM
	Needham & Company LLC Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT) www.americanbankingnews.com - March 28 at 9:16 PM
	BidaskClub Lowers Intercept Pharmaceuticals (ICPT) to Strong Sell www.americanbankingnews.com - March 28 at 12:34 AM
	Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - March 25 at 5:24 PM
	Intercept Pharmaceuticals (ICPT) Downgraded by Goldman Sachs www.americanbankingnews.com - March 25 at 7:44 AM
	$38.55 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter www.americanbankingnews.com - March 24 at 4:49 AM
	Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018 finance.yahoo.com - March 23 at 8:47 AM
	Intercept Pharmaceuticals' (ICPT) "Hold" Rating Reaffirmed at Oppenheimer www.americanbankingnews.com - March 21 at 7:48 PM
	New Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production finance.yahoo.com - March 21 at 9:36 AM
	Edited Transcript of ICPT earnings conference call or presentation 14-Feb-18 1:30pm GMT finance.yahoo.com - March 21 at 9:36 AM
	Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue? finance.yahoo.com - March 16 at 6:05 PM
	CORRECTING and REPLACING -- Intercept to Present at Upcoming Conference finance.yahoo.com - March 13 at 6:57 PM
	Intercept Pharmaceuticals Inc to Post FY2021 Earnings of $10.38 Per Share, Wedbush Forecasts (ICPT) www.americanbankingnews.com - March 12 at 9:41 AM
	Intercept Pharmaceuticals (ICPT) Earns Outperform Rating from Wedbush www.americanbankingnews.com - March 9 at 8:11 AM
	Research finds female analysts are more accurate, make bolder calls - CNBC www.cnbc.com - March 8 at 6:10 PM
	$38.46 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter www.americanbankingnews.com - March 7 at 1:59 PM
	Intercept Pharmaceuticals Inc (ICPT) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 6 at 1:39 PM
	Hudson Bay Capital Management LP Invests $1.75 Million in Intercept Pharmaceuticals Inc (ICPT) Stock www.americanbankingnews.com - March 2 at 12:49 PM
	Altrinsic Global Advisors LLC Grows Stake in Intercept Pharmaceuticals Inc (ICPT) www.americanbankingnews.com - March 2 at 4:16 AM
	Senvest Management LLC Increases Holdings in Intercept Pharmaceuticals Inc (ICPT) www.americanbankingnews.com - February 26 at 4:02 PM
	Spark Investment Management LLC Has $10.58 Million Holdings in Intercept Pharmaceuticals Inc (ICPT) www.americanbankingnews.com - February 25 at 2:31 PM

Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement

Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff